Prostate cancer accounts for a significant proportion of cancer diagnoses in Canadian men. Over the past decade, the therapeutic landscape for the management of metastatic prostate cancer has undergone rapid changes. Novel strategies use hormonal agents, chemotherapy, homologous recombination repair inhibitors, and radioligand therapy or combination strategies in addition to androgen deprivation therapy. In this review, we summarize the available data addressing key therapeutic areas along the disease continuum and focus on practical aspects for general practitioners in oncology managing patients with metastatic prostate cancer.
Keywords: ARAT; BRCA1/2; CAGPO; Canadian Association of General Practitioners in Oncology; PARP inhibitors; PSMA; androgen receptor axis-targeted drugs; breast cancer gene 1/2; docetaxel; poly ADP ribose polymerase inhibitors; prostate cancer; prostate-specific membrane antigen.